• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc (Amendment)

    2/13/24 4:39:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVDL alert in real time by email
    SC 13G/A 1 avdl212240sc13ga2.htm AMENDMENT NO. 2

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Avadel Pharmaceuticals plc
    (Name of Issuer)
     
    American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share
    (Title of Class of Securities)
     
    05337M104
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    ☑ Rule 13d-1(c)

    o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      
     

     

    CUSIP No. 05337M104 13G/A Page 2 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    Tontine Asset Associates, LLC

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

     

    (b) o

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

     

    6

    SHARED VOTING POWER

    3,539,782

     

    7

    SOLE DISPOSITIVE POWER

    -0-

     

    8

    SHARED DISPOSITIVE POWER

    3,539,782

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,539,782

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.94%

     

    12

    TYPE OF REPORTING PERSON

    OO

     

     

      
     

     

    CUSIP No. 05337M104 13G/A Page 3 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    Tontine Capital Overseas Master Fund II, L.P.

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

     

    (b) o

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

     

    6

    SHARED VOTING POWER

    3,539,782

     

    7

    SOLE DISPOSITIVE POWER

    -0-

     

    8

    SHARED DISPOSITIVE POWER

    3,539,782

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,539,782

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.94%

     

    12

    TYPE OF REPORTING PERSON

    PN

     

     

      
     

     

    CUSIP No. 05337M104 13G/A Page 4 of 9 Pages

     

    1

    NAME OF REPORTING PERSON

    Jeffrey L. Gendell

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

     

    (b) o

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION 

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    70,000

     

    6

    SHARED VOTING POWER

    5,615,350

     

    7

    SOLE DISPOSITIVE POWER

    70,000

     

    8

    SHARED DISPOSITIVE POWER

    5,615,350

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,685,350

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.33%

     

    12

    TYPE OF REPORTING PERSON

    IN

     

     

      
     

     

    CUSIP No. 05337M104 13G/A Page 5 of 9 Pages

     

    Item 1(a).NAME OF ISSUER

     

    The name of the issuer is Avadel Pharmaceuticals plc (the “Company”).

     

    Item 1(b).ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES

     

    The Company’s principal executive offices are located at 10 Earlsfort Terrace, Dublin 2, D02 T380 Ireland.

     

    Item 2(a).NAME OF PERSON FILING

     

    This statement is filed by:

     

      (i) Tontine Capital Overseas Master Fund II, L.P. (“TCOM II”), a limited partnership organized under the laws of the State of Delaware, with respect to 3,539,782 American Depositary Shares directly owned by TCOM II;

     

      (ii) Tontine Asset Associates, LLC, a limited liability company organized under the laws of the State of Delaware (“TAA”), which serves as general partner of TCOM II, with respect to the American Depositary Shares directly owned by TCOM II; and

     

      (iii)

    Jeffrey L. Gendell, a United States citizen (“Mr. Gendell”), with respect to 3,539,782 American Depositary Shares directly owned by TCOM II, 2,075,568 American Depositary Shares directly owned by Tontine Financial Partners, L.P., a limited partnership organized under the laws of the State of Delaware (“TFP”), and 70,000 American Depositary Shares directly owned by Mr. Gendell. Mr. Gendell serves as the Managing Member of TAA and also serves as the Managing Member of Tontine Management, L.L.C., a limited liability company organized under the laws of the State of Delaware (“TM”), which serves as general partner of TFP.

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    Item 2(b).ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE

     

    The address of the business office of each of the Reporting Persons is 1 Sound Shore Drive, Suite 304, Greenwich, CT 06830-7251.

     

    Item 2(c).CITIZENSHIP

     

    See Item 2(a) above.

     

    Item 2(d).TITLE OF CLASS OF SECURITIES

     

    American Depositary Shares, each representing one Ordinary Share, nominal value $0.01 per share (the “American Depositary Shares”).

     

      
     

     

    CUSIP No. 05337M104 13G/A Page 6 of 9 Pages

     

    Item 2(e).CUSIP NUMBER

     

    05337M104

     

    Item 3.IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) o Broker or dealer registered under Section 15 of the Act;
           
      (b) o Bank as defined in Section 3(a)(6) of the Act;
           
      (c) o Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) o

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

           
      (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) o

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

           
      (i) o

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

           
      (j) o A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) o Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
           
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable. 

     

      
     

     

    CUSIP No. 05337M104 13G/A Page 7 of 9 Pages

     

    Item 4.OWNERSHIP

     

      A. Tontine Asset Associates, LLC
        (a) Amount beneficially owned:  3,539,782

      

    (b)

    Percent of class: 3.94%.  This percentage and those used elsewhere in this Schedule 13G/A are calculated based upon the 89,805,653 ordinary shares issued and outstanding at November 6, 2023, as set forth in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 8, 2023.

           
        (c) (i) Sole power to vote or direct the vote:  -0- 
          (ii) Shared power to vote or direct the vote:  3,539,782
          (iii) Sole power to dispose or direct the disposition of:  -0- 
          (iv) Shared power to dispose or direct the disposition of:  3,539,782
         
      B. Tontine Capital Overseas Master Fund II, L.P.
        (a) Amount beneficially owned:  3,539,782
        (b) Percent of class:  3.94%
        (c) (i) Sole power to vote or direct the vote:  -0-
          (ii) Shared power to vote or direct the vote:  3,539,782
          (iii) Sole power to dispose or direct the disposition of:  -0- 
          (iv) Shared power to dispose or direct the disposition of:  3,539,782
         
      C. Jeffrey L. Gendell
        (a) Amount beneficially owned:  5,685,350
        (b) Percent of class:  6.33%
        (c) (i) Sole power to vote or direct the vote:  70,000
          (ii) Shared power to vote or direct the vote:  5,615,350
          (iii) Sole power to dispose or direct the disposition of:  70,000
          (iv) Shared power to dispose or direct the disposition of:  5,615,350
                   

     

       
     

     

    CUSIP No. 05337M104 13G/A Page 8 of 9 Pages

     

    Item 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable. 

     

    Item 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    TAA, the general partner of TCOM II, has the power to direct the affairs of TCOM II, including directing the receipt of dividends from, or the proceeds from the sale of, the American Depositary Shares directly owned by TCOM II. Mr. Gendell is the Managing Member of TAA and in that capacity directs its operations. 

     

    TM, the general partner of TFP, has the power to direct the affairs of TFP, including directing the receipt of dividends from, or the proceeds from the sale of, the American Depositary Shares directly owned by TFP. Mr. Gendell is the Managing Member of TM and in that capacity directs its operations. 

     

    Item 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

     

    Not applicable. 

     

    Item 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    Not applicable. 

     

    Item 9.NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable. 

     

    Item 10.CERTIFICATION

     

    Each of the Reporting Persons hereby makes the following certification:

     

     

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

       
     

     

    CUSIP No. 05337M104 13G/A Page 9 of 9 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATE: February 13, 2024

     

     

    /s/ Jeffrey L. Gendell  
    Jeffrey L. Gendell, individually, and as managing member of Tontine Asset Associates, LLC, for itself and as the general partner of Tontine Capital Overseas Master Fund II, L.P.  

     

     

     

     

     

    Get the next $AVDL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVDL

    DatePrice TargetRatingAnalyst
    2/11/2025$12.00Buy
    Deutsche Bank
    6/12/2024$27.00Buy
    Rodman & Renshaw
    3/5/2024$27.00 → $29.00Outperform
    Oppenheimer
    3/5/2024$21.00 → $25.00Buy
    H.C. Wainwright
    3/5/2024$20.00 → $22.00Buy
    Needham
    2/6/2024$21.00Buy
    UBS
    11/30/2022$6.50 → $11.00Hold → Buy
    Jefferies
    8/10/2022$6.00 → $8.00Buy → Hold
    Jefferies
    More analyst ratings

    $AVDL
    Financials

    Live finance-specific insights

    See more
    • Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

      -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in

      5/7/25 7:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

      DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are

      4/30/25 8:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

      DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here a

      2/24/25 4:05:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    SEC Filings

    See more

    $AVDL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AVDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AVDL
    Leadership Updates

    Live Leadership Updates

    See more

    $AVDL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 10-Q filed by Avadel Pharmaceuticals plc

      10-Q - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

      5/7/25 9:20:30 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

      5/7/25 7:07:12 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

      5/6/25 2:59:18 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      1/22/25 4:13:34 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      1/14/25 4:24:12 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ende Eric J bought $235,218 worth of Ordinary Shares (30,000 units at $7.84), increasing direct ownership by 17% to 208,900 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      1/14/25 4:22:57 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Avadel Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      2/11/25 7:00:38 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Avadel Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00

      6/12/24 7:06:25 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Avadel Pharmaceuticals with a new price target

      Oppenheimer reiterated coverage of Avadel Pharmaceuticals with a rating of Outperform and set a new price target of $29.00 from $27.00 previously

      3/5/24 7:51:39 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

      DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build

      2/24/25 8:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

      DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin

      1/22/25 8:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals to Join Russell 3000® Index

      DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit

      6/27/24 4:05:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the se

      5/8/25 4:05:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

      -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in

      5/7/25 7:00:00 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

      - With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") has ruled in favor of Avadel, overturning important parts of the injunction imposed by the U.S. District Court for the District of Delaware (the "Delaware Court") rega

      5/6/25 12:30:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gen. Counsel & Corp. Secretary Seurer Jerad G. was granted 14,700 units of Ordinary Shares, increasing direct ownership by 167% to 23,495 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      3/7/25 4:09:00 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Mchugh Thomas S was granted 12,600 units of Ordinary Shares, increasing direct ownership by 14% to 100,400 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      3/7/25 4:07:45 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Divis Gregory J was granted 52,000 units of Ordinary Shares, increasing direct ownership by 33% to 211,100 units (SEC Form 4)

      4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

      3/7/25 4:06:44 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

      SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

      11/14/24 6:10:30 AM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

      SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

      11/13/24 5:58:54 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

      SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

      11/13/24 5:00:57 PM ET
      $AVDL
      Biotechnology: Pharmaceutical Preparations
      Health Care